Remus Pharmaceuticals (NSE:REMUS) Notes Receivable: ₹0 Mil (As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
59 GF Score
Price ₹767.40
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Notes Receivable?

Remus Pharmaceuticals NSE:REMUS +2.86% 59 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 59/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Remus Pharmaceuticals Notes Receivable Related Terms

Remus Pharmaceuticals Notes Receivable Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Notes Receivable Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:REMUS
59GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Notes Receivable too high?
Remus Pharmaceuticals' current Notes Receivable is ₹0 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Notes Receivable compare to MCK and CAH?
Remus Pharmaceuticals' Notes Receivable of ₹0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Distribution company?
A good Notes Receivable depends on the Medical Distribution industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹767.40 — trading 63% below its estimated fair value. The current Notes Receivable is ₹0 Mil. Remus Pharmaceuticals' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹767.40 is trading 63% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹767.40 (63% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
59GF Score

Get the complete analysis for NSE:REMUS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹767.40
Price
₹2,071.36
GF Value